Trends in der Behandlung der renalen Anämie

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Dr. Andras T. Deak

Klinische Abteilung für Nephrologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz


AutorIn: Univ.-Prof. Dr. Alexander Rosenkranz

Klinische Abteilung für Nephrologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz


1 Locatelli F., Pisoni R.L., Combe C., Bommer J., Andreucci V.E., Piera L., Greenwood R., Feldman H.I., Port F.K., Held PJ..: Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19 (1): 121–132
2 Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., Reddan D.: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355 (20): 2085–2098
3 Drueke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D., Burger H.U., Scherhag A.: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355 (20): 2071–2084
4 Pfeffer M.A., Burdmann E.A., Chen C.Y., Cooper M.E., de Zeeuw D., Eckardt K.U., Feyzi J.M., Ivanovich P., Kewalramani R., Levey A.S. et al.: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361 (21): 2019–2032
5 Williams A.W., Dwyer A.C., Eddy A.A., Fink J.C., Jaber B.L., Linas S.L., Michael B., O’Hare A.M., Schaefer H.M., Shaffer R.N. et al.: Critical and honest conversations: the evidence behind the „Choosing Wisely“ campaign recommendations by the American Society of Nephrology. Clin J Am Soc Nephrol 2012; 7 (10): 1664–1672
6 Thamer M., Zhang Y., Kshirsagar O., Cotter D.J., Kaufman J.S.: Erythropoiesis-Stimulating Agent Use Among Non-Dialysis-Dependent CKD Patients Before and After the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Using a Large US Health Plan Database. Am J Kidney Dis 2014
7 Gaweda A.E., Aronoff G.R., Jacobs A.A., Rai S.N., Brier M.E.: Individualized anemia management reduces hemoglobin variability in hemodialysis patients. J Am Soc Nephrol 2014; 25 (1): 159–166
8 Drueke T.B., Parfrey P.S.: Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int 2012; 82 (9): 952–960
9 Prabhu M.V., Nayak A., Sridhar G., Subhramanyam S.V., Nayak K.S.: Maximizing the erythropoetin response: iron strategies. Contrib Nephrol 2012; 178: 95–99
10 Coyne D.W., Kapoian T., Suki W., Singh A.K., Moran J.E., Dahl N.V., Rizkala A.R.: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18 (3): 975–984
11 Kapoian T., O’Mara N.B., Singh A.K., Moran J., Rizkala A.R., Geronemus R., Kopelman R.C., Dahl N.V., Coyne D.W.: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008; 19 (2): 372–379
12 Fishbane S., Berns J.S.: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoetin. Kidney Int 2005; 68 (3): 1337–1343
13 Qunibi W.Y., Martinez C., Smith M., Benjamin J., Mangione A., Roger S.D.: A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011; 26 (5): 1599–1607
14 Macdougall I.C., Bock A.H., Carrera F., Eckardt K.U., Gaillard C., Van Wyck D., Roubert B., Nolen J.G., Roger S.D.: FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014
15 Fishbane S., Hazzan A.D.: Anaemia: FIND-CKD: intravenous iron in predialysis CKD. Nat Rev Nephrol 2014; 10 (9): 488–489
16 Macdougall I.C., Strauss W.E., McLaughlin J., Li Z., Dellanna F., Hertel J.: A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol 2014; 9 (4): 705–712
17 Kohgo Y., Ikuta K., Ohtake T., Torimoto Y., Kato J.: Body iron metabolism and pathophysiology of iron overload. Int J Hematol 2008; 88 (1): 7–15
18 Van Buren P., Velez R.L., Vaziri N.D., Zhou X.J.: Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. Int Urol Nephrol 2012; 44 (2): 499–507
19 Kuragano T., Matsumura O., Matsuda A., Hara T., Kiyomoto H., Murata T., Kitamura K., Fujimoto S., Hase H., Joki N. et al.: Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int 2014
20 Bailie G.R., Larkina M., Goodkin D.A, Li Y., Pisoni R.L., Bieber B., Mason N., Tong L., Locatelli F., Marshall M.R. et al.: Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 2014
21 Johnson D.W., Pascoe E.M., Badve S.V., Dalziel K., Cass A., Clarke P., Ferrari P., McDonald S.P., Morrish A.T., Pedagogos E. et al.: A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoetin Resistance With Oxpentifylline (HERO) Trial. Am J Kidney Dis 2014

Neph 03|2014

Herausgeber: Österreichische Gesellschaft für Nephrologie, Univ.- Prof. Dr. Alexander Rosenkranz, Klinische Abteilung für Nephrologie, Medizinische Universität Graz.
Publikationsdatum: 2014-09-22